Pharmacogenetic markers of drug efficacy and toxicity

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 1, 2015, Pages 61-70

  Yip, V L M ^a,b   Hawcutt, D B ^a,c   Pirmohamed, M ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTICOAGULANT AGENT; BUCINDOLOL; CARBAMAZEPINE; CISPLATIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOCHROME P450 2D6; DALCETRAPIB; ELIGLUSTAT; IVACAFTOR; VINCRISTINE; WARFARIN; ANTINEOPLASTIC AGENT; DRUG; PHARMACOLOGICAL BIOMARKER;

ADCY9 GENE; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DRESS SYNDROME; DRUG CHOICE; DRUG EFFICACY; DRUG TOXICITY; DRUG TREATMENT FAILURE; GENE; GENOTYPE; GENOTYPING TECHNIQUE; HEART FAILURE; HEREDITY; HUMAN; HYPERSENSITIVITY; META ANALYSIS (TOPIC); OTOTOXICITY; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ADVERSE DRUG REACTION; DRUG DEVELOPMENT; PERSONALIZED MEDICINE; SYSTEMS THEORY;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; DRUG DISCOVERY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PRECISION MEDICINE; SYSTEMS THEORY;

EID: 84958526546     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.135     Document Type: Article

References (75)

1. E15: I. Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories
2. Ehmann, F., Caneva, L. & Papaluca, M. European Medicines Agency initiatives and perspectives on pharmacogenomics. Br. J. Clin. Pharmacol. 77, 612-617 (2014).
3. US Food and Drug Administration. Paving the Way for Personalized Medicine. FDA?s Role in a New Era of Medical Product Development (2014).
4. Academy of Medical Sciences. Realising the Potential of Stratified Medicines (Academy of Medical Sciences, London, 2013).
5. Kirley, K., Qato, D.M., Kornfield, R., Stafford, R.S. & Alexander, G.C. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ. Cardiovasc. Qual. Outcomes 5, 615-621 (2012).
6. Pirmohamed, M., Kamali, F., Daly, A.K. & Wadelius, M. Oral anticoagulation: a critique of recent advances and controversies. Trends Pharmacol. Sci. 36, 153-163 (2015).
7. McCormack, M., et al. HLA-A3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134-1143 (2011).
8. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
9. Kimmel, S.E., et al. A pharmacogenetic vs. a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369, 2283-2293 (2013).
10. Pirmohamed, M., et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369, 2294-2303 (2013).
11. Perera, M.A., et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 382, 790-796 (2013).
12. Drozda, K., et al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet. Genom. 25, 73-81 (2015).
13. Pirmohamed, M., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329, 15-19 (2004).
14. Biss, T.T., et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 119, 868-873 (2012).
15. Nowak-Geottl, U., et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood 116, 6101-6105 (2010).
16. Moreau, C., et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood 119, 861-867 (2012).
17. Kato, Y., et al. Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug Metab. Pharmacokinet. 26, 295-299 (2011).
18. Nguyen, N., Anley, P., Margaret, Y.Y., Zhang, G., Thompson, A.A. & Jennings, L.J. Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Pediatr. Cardiol. 34, 984-990 (2013).
19. Hirai, K., et al. Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients. Drug Metab. Pharmacokinet. 28, 132-137 (2013).
20. Hawcutt, D., et al. Pharmacogenetics of warfarin in a pediatric population: time in therapeutic range, initial and stable dosing and adverse effects. Pharmacogenom. J. 14, 542-548 (2014).
21. National Institute for Health and Care Excellence. Venous Thromboembolism Overview . Accessed 30 March 2015
22. Pfeilschifter, W., Luger, S., Brunkhorst, R., Lindhoff-Last, E. & Foerch, C. The gap between trial data and clinical practice- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. Cerebrovasc. Dis. 36, 115-119 (2013).
23. Steollberger, C. & Finsterer, J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz, 1-6 (2015).
24. Brambila-Tapia, A. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Rev. Invest. Clin. 65, 445-454 (2013).
25. Heartter, S., et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br. J. Clin. Pharmacol. 74, 490-500 (2012).
26. Mueck, W., Kubitza, D. & Becka, M. Co-Administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br. J. Clin. Pharmacol. 76, 455-466 (2013).
27. Par-e, G., et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 127, 1404-1412 (2013).
28. Mehta, A. Epidemiology and natural history of Gaucher?s disease. Eur. J. Intern. Med. 17 (suppl.), S2-S5 (2006).
29. Bennett, L.L. & Mohan, D. Gaucher disease and its treatment options. Ann. Pharmacother. 47, 1182-1193 (2013).
30. Peterschmitt, M.J., et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (genz-112638) after single doses, multiple doses, and food in healthy volunteers. J. Clin. Pharmacol. 51, 695-705 (2011).
31. Poole, R. Eliglustat: first global approval. Drugs 74, 1829-1836 (2014).
32. Filipski, K.K., Mechanic, L.E., Long, R. & Freedman, A.N. Pharmacogenomics in oncology care. Front. Genet. 5 (2014).
33. Sosman, J.A., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714 (2012).
34. Ramsey, B.W., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663-1672 (2011).
35. Eckford, P.D., Li, C., Ramjeesingh, M. & Bear, C.E. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J. Biol. Chem. 287, 36639-36649 (2012).
36. Davies, J., et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomized controlled trial. Lancet Respir. Med. 1, 630-638 (2013).
37. Yu, H., et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J. Cystic Fibrosis 11, 237-245 (2012).
38. Boyle, M.P., et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomized controlled trial. Lancet Respir. Med. 2, 527-538 (2014).
39. Becquemont, L. HLA: a pharmacogenomics success story. Pharmacogenomics 11, 277-281 (2010).
40. Hetherington, S., et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23, 1603-1614 (2001).
41. Mallal, S., et al. Association between presence of HLA-B∗5701, HLADR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
42. Hetherington, S., et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
43. Nolan, D., Martin, A., Almeida, C. & Mallal, S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort Study. Clin. Infect. Dis. 99 (2006).
44. Chen, Z., Liew, D. & Kwan, P. Effects of a HLA-B∗15: 02 screening policy on antiepileptic drug use and severe skin reactions. Neurology 83, 2077-2084 (2014).
45. McCormack, M., et al. HLA-A3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134-1143 (2011).
46. Ozeki, T., et al. Genome-wide association study identifies HLAA 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20, 1034-1041 (2011).
47. Yip, V.L.M., Alfirevic, A. & Pirmohamed, M. Genetics of immunemediated adverse drug reactions: a comprehensive and clinical review. Clin. Rev. Allerg. Immunol. 1-11 (2014).
48. Diouf, B., et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313, 815-823 (2015).
49. Brock, P.R., et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J. Clin. Oncol. 30, 2408-2417 (2012).
50. Ekborn, A., Laurell, G., Andersson, A., Wallin, I., Eksborg, S. & Ehrsson, H. Cisplatin-induced hearing loss: influence of the mode of drug administration in the guinea pig. Hear. Res. 140, 38-44 (2000).
51. Ross, C.J., et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41, 1345-1349 (2009).
52. Yang, J.J., et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin. Pharmacol. Ther. 94, 252-269 (2013).
53. Xu, H., et al. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat. Genet. (2015).
54. Schwartz, G.G., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089-2099 (2012).
55. Tardif, J.-C., et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ. Cardiovasc. Genet. (2015).
56. Tardif, J.-C., Lesage, F., Harel, F., Romeo, P. & Pressacco, J. Imaging biomarkers in atherosclerosis trials. Circ. Cardiovasc. Imaging 4, 319-333 (2011).
57. The Beta Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. 344, 1659-1667 (2001).
58. Liggett, S.B., et al. A polymorphism within a conserved b(1)-Adrenergic receptor motif alters cardiac function and b-blocker response in human heart failure. Proc. Natl. Acad. Sci. U. S. A. 103, 11288-11293 (2006).
59. Bristow, M.R., et al. An a2C-Adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the b-blocker bucindolol in chronic heart failure. Circ. Heart Fail. 3, 21-28 (2010).
60. O?Connor, C.M., et al. Combinatorial pharmacogenetic interactions of bucindolol and b1, a2c adrenergic receptor polymorphisms. PLoS One 7, e44324 (2012).
61. Andrew Clayton, T., et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077 (2006).
62. Karnes, J.H., et al. Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley Interdisciplinary Rev. Syst. Biol. Med. 6, 125-135 (2014).
63. Laaksonen, R., et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One 1, e97 (2006).
64. Dahlin, A. & Tantisira, K.G. Integrative systems biology approaches in asthma pharmacogenomics. Pharmacogenomics 13, 1387-1404 (2012).
65. Meadows, N.A., Morrison, A., Brindley, D.A., Schuh, A. & Barker, R.W. An evaluation of regulatory and commercial barriers to stratified medicine development and adoption. Pharmacogenomics J 15, 6-12 (2015).
66. Hammond, M.E.H., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch. Pathol. Lab. Med. 134, 907-922 (2010).
67. Lyman, G.H., Cosler, L.E., Kuderer, N.M. & Hornberger, J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer. Cancer 109, 1011-1018 (2007).
68. Pirmohamed, M. & Hughes, D.A. Pharmacogenetic tests: the need for a level playing field. Nat. Rev. Drug Discov. 12, 3-4 (2013).
69. Stanek, E.J., et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91, 450 (2012).
70. Stead, W.W., Searle, J.R., Fessler, H.E., Smith, J.W. & Shortliffe, E.H. Biomedical informatics: changing what physicians need to know and how they learn. Acad. Med. 86, 429-434 (2011).
71. Gottesman, O., et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet. Med. 15, 761-771 (2013).
72. Roberts, J.D., et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomized, proof-of-concept trial. Lancet 379, 1705-1711 (2012).
73. Johnson, J.A., Elsey, A.R., Clare-Salzler, M.J., Nessl, D., Conlon, M. & Nelson, D.R. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics 14, 723-726 (2013).
74. Pulley, J.M., et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92, 87-95 (2012).
75. US Food and Drug Administration. http: //labels.